Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V. News
Sep 3, 2025 - seekingalpha.com
NewAmsterdam Pharma Company N.V. (NAMS) Presents At Citi's Biopharma Back To School Conference Transcript
Aug 25, 2025 - globenewswire.com
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September
Aug 21, 2025 - prnewswire.com
Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site
Aug 18, 2025 - globenewswire.com
NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib
NewAmsterdam Pharma Company N.V. Quantitative Score
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
NewAmsterdam Pharma Company N.V. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
NewAmsterdam Pharma Company N.V. Financials
Table Compare
Compare NAMS metrics with: | |||
|---|---|---|---|
Earnings & Growth | NAMS | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | NAMS | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | NAMS | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | NAMS | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
NewAmsterdam Pharma Company N.V. Income
NewAmsterdam Pharma Company N.V. Balance Sheet
NewAmsterdam Pharma Company N.V. Cash Flow
NewAmsterdam Pharma Company N.V. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
NewAmsterdam Pharma Company N.V. Executives
| Name | Role |
|---|---|
| Dr. Michael Harvey Davidson FACC, Facp., M.D. | Chief Executive Officer, President, Executive Board Member & Director |
| Mr. Douglas F. Kling | Chief Operating Officer |
| Mr. Mayur Amrat Somaiya | Chief Financial Officer |
| Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. | Founder, Chief Scientific Officer, Member of Executive Board & Director |
| Ms. Juliette Audet M.B.A., M.Sc. | Chief Strategy & Business Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Michael Harvey Davidson FACC, Facp., M.D. | Chief Executive Officer, President, Executive Board Member & Director | 1956 | 1.12M | |
| Mr. Douglas F. Kling | Chief Operating Officer | Male | 1973 | 913.74K |
| Mr. Mayur Amrat Somaiya | Chief Financial Officer | Male | 1974 | 841.24K |
| Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. | Founder, Chief Scientific Officer, Member of Executive Board & Director | 1954 | 813.08K | |
| Ms. Juliette Audet M.B.A., M.Sc. | Chief Strategy & Business Officer | Female | 1987 | 653.04K |
NewAmsterdam Pharma Company N.V. Insider Trades
| Date | 15 Sep |
| Name | Topper James N |
| Role | Director |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 660 |
| Date | 9 Sep |
| Name | Kooij Louise Frederika |
| Role | Chief Accounting Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 150000 |
| Date | 9 Sep |
| Name | Kooij Louise Frederika |
| Role | Chief Accounting Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 53104 |
| Date | 9 Sep |
| Name | Kooij Louise Frederika |
| Role | Chief Accounting Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 96896 |
| Date | 9 Sep |
| Name | Kooij Louise Frederika |
| Role | Chief Accounting Officer |
| Transaction | Disposed |
| Type | M-Exempt |
| Shares | 150000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 15 Sep | Topper James N | Director | Acquired | P-Purchase | 660 |
| 9 Sep | Kooij Louise Frederika | Chief Accounting Officer | Acquired | M-Exempt | 150000 |
| 9 Sep | Kooij Louise Frederika | Chief Accounting Officer | Disposed | S-Sale | 53104 |
| 9 Sep | Kooij Louise Frederika | Chief Accounting Officer | Disposed | S-Sale | 96896 |
| 9 Sep | Kooij Louise Frederika | Chief Accounting Officer | Disposed | M-Exempt | 150000 |